The active role and clinical value of cephalosporins in modern antibiotic therapy, with a focus on supply chain dynamics and future scenarios.
What Are Third Generation Cephalosporins?
Cephalosporins belong to the β‑lactam class and act by inhibiting bacterial cell wall synthesis through binding to penicillin‑binding proteins (PBPs). Their efficacy depends on the time during which the free drug concentration remains above the MIC—a key principle in the PK/PD optimization of β‑lactams.
Historically pillars of therapy for many community‑acquired and hospital‑acquired infections, cephalosporins continue to play an important role thanks to their favorable safety profile, broad flexibility of use—from empirical to targeted therapy—and predictable spectrum.
In a European setting where resistance remains high (e.g., rising incidence of carbapenem‑resistant Klebsiella pneumoniae between 2019 and 2023), consolidated molecules remain central when selected according to local epidemiology and resistance mechanisms. Authoritative guidelines also emphasize that choosing the appropriate β‑lactam, rapidly revising empirical therapy based on culture results, and reducing treatment duration are essential to curb antimicrobial resistance.
When and Why to Choose Cephalosporins
The choice of cephalosporins today is primarily based on a balanced spectrum of activity and strong microbiological predictability. These drugs offer reliable coverage against community pathogens as well as several hospital Gram‑negatives, allowing clinicians to initiate targeted empirical therapy that can be easily adjusted (de‑escalated) when culture data become available.
Beyond versatility, one of the major strengths of this class is its safety and tolerability. Generally well tolerated, cephalosporins represent a valuable “organ‑sparing” alternative to more toxic classes such as aminoglycosides or polymyxins. Numerous meta‑analyses confirm this advantage, particularly highlighting a lower incidence of nephrotoxicity compared to traditional comparators.
From an antimicrobial stewardship perspective, rational use of cephalosporins plays a crucial role. Preferring the right cephalosporin for a specific pathogen—rather than immediately resorting to carbapenems or ultra‑broad therapies—helps mitigate the development of resistance mechanisms such as ESBL, AmpC, and carbapenemases. This approach is especially effective in scenarios such as hospital‑acquired pneumonia or complicated urinary tract infections, where certain cephalosporins (sometimes combined with β‑lactamase inhibitors) remain the cornerstone of initial empirical therapy.
However, it is essential to recognize their clinical limitations. In high‑inoculum extra‑urinary infections where ESBL or AmpC production is documented or strongly suspected, guidelines discourage the use of third‑generation cephalosporins in favor of more robust alternatives. Additionally, resistance mechanisms such as altered PBPs (e.g., PBP3 modifications in E. coli) or permeability changes can compromise efficacy against some Gram‑negative strains, requiring careful clinical monitoring.
Cephalosporins and Antimicrobial Resistance
Across Europe, concerning trends are observed in MDR Gram negative resistance, such as carbapenem resistant K. pneumoniae. This drives more selective use of third generation cephalosporins and more frequent reliance on “enhanced” combinations in high risk settings—always with early review to allow de escalation whenever possible.
ESBLs, plasmid or chromosomal AmpC, and PBP alterations (such as PBP3 modifications in E. coli) reduce susceptibility to third‑generation cephalosporins. In parallel, efflux mechanisms and porin loss in non‑fermenters further complicate therapy.
Choosing the appropriate cephalosporin—rather than ultra broad agents—reduces selective pressure on carbapenems and other ecologically impactful classes. Timely de escalation has been associated with at least non inferior outcomes, and in some ICU settings, even lower mortality.
European Market and Supply Chain Challenges
The European cephalosporin market is characterized by structurally high demand, driven by persistent hospital infections and MDR pathogens that—according to the ECDC—continue to shape public health strategies. These molecules remain essential components of formularies for respiratory, urinary, and intra‑abdominal syndromes, aligned with stewardship principles and AMR 2030 goals.
However, sector sustainability is threatened by deep structural challenges, including heavy geographic dependence on Asia for APIs—with European production costs 20–40% higher than in India and China—and procurement policies often focused solely on price. This increases supply chain vulnerability, especially given the technical complexity of sterile manufacturing and regulatory or energy‑related shocks.
Although the shortages experienced in 2023–2024 prompted EMA and the MSSG to strengthen centralized monitoring and preparedness for the 2025–2026 seasons, future resilience will depend on multisourcing strategies, “strategic but rational” stockpiles, and closer collaboration between authorities and purchasing bodies to ensure continuity of therapy even during seasonal demand peaks.
Multisourcing API/KSM, rational stockpiling, production redundancy, transparent lead times, and stakeholder cooperation are recognized levers to reduce distribution‑chain risks.
Research & Development: Evolution of the Class and Clinical Implications
Therapeutic innovation in cephalosporins has expanded clinical options significantly, particularly through new β lactam/β lactamase inhibitor combinations such as ceftazidime/avibactam, which in integrated analyses and phase 3 trials have demonstrated superior efficacy and safety compared to historical comparators in treating KPC and OXA producing pathogens.
Additionally, innovative agents such as cefiderocol—a “siderophore” cephalosporin that enhances Gram‑negative uptake using iron‑transport mechanisms (discussed previously on our blog)—offer new therapeutic avenues. Nonetheless, despite documented non‑inferiority in complicated urinary infections and HAP/VAP, its use must remain cautious due to mortality signals observed in the CREDIBLE‑CR trial for subgroups such as Acinetobacter.
Alongside molecular innovation, optimizing drug exposure through prolonged or continuous infusion to maximize fT > MIC remains a cornerstone of therapy, especially in critically ill patients. Although mortality data are heterogeneous (e.g., the BLING III study), individualized dosing through therapeutic drug monitoring (TDM) is strongly recommended to ensure adequate target attainment.
In this evolving landscape, the availability of new agents does not render established cephalosporins obsolete (such as ceftriaxone, ceftazidime, cefoperazone, cefotaxime, and cefuroxime, which we will cover separately on our blog). Rather, it strengthens their rational use, allowing the most advanced therapeutics to be preserved for genuinely resistant infections.
OLD PHARMA’s Contribution
Supporting the availability of essential molecules.
Commitment to maintaining consolidated cephalosporins in the portfolio, aligned with EMA/MSSG recommendations for continuity of supply.
Manufacturing quality and supply continuity.
Investments in sterility processes, supply chain robustness, and early‑warning systems for potential disruptions, enabling timely mitigation with stakeholders.
Collaboration with healthcare stakeholders.
Support for stewardship programs (rapid diagnostics, de‑escalation pathways, training) and procurement models that reward resilience alongside pricing.
Responsible approach.
Transparency on availability and timelines, avoiding promotional messaging and emphasizing appropriate use in line with clinical guidelines.
OLD PHARMA positions itself as a reliable, responsible partner for availability, quality, and collaboration—supporting sustainable, evidence‑based healthcare.
If you wish to explore the role of specific cephalosporins within your organization or inquire about availability, the OLD PHARMA team is available for a non binding technical discussion.
Disclosure: This content is for informational purposes only and does not replace medical advice or individualized clinical/prescriptive guidance.
Reference
- Tamma PD, et al. IDSA 2024 Guidance on the Treatment of AMR Gram‑negative Infections. Clin Infect Dis. 2024. DOI:10.1093/cid/ciae403. [academic.oup.com]
- De Waele JJ, et al. Antimicrobial de‑escalation in ICU. Intensive Care Med. 2020;46:236‑244. DOI:10.1007/s00134-019-05871-z. [link.springer.com]
- Castanheira M, Simner PJ, Bradford PA. ESBL update. JAC‑Antimicrob Resist. 2021;3(3):dlab092. DOI:10.1093/jacamr/dlab092. [academic.oup.com]
- Freire S, et al. PBP3 modification and cephalosporin resistance. J Antimicrob Chemother. 2024;79(4):930–932. DOI:10.1093/jac/dkae020. [academic.oup.com]
- Pogue JM, et al. C/T vs aminoglicosidi/polimixine in DR‑P. aeruginosa. Clin Infect Dis. 2020;71(2):304–310. DOI:10.1093/cid/ciz816. [academic.oup.com]
- Puzniak L, et al. C/T real‑world. Antimicrob Resist Infect Control. 2021;10:68. DOI:10.1186/s13756-021-00933-8. [link.springer.com]
- Torres A, et al. CAZ/AVI pooled phase 3. J Antimicrob Chemother. 2023;78(11):2672–2682. DOI:10.1093/jac/dkad280. [academic.oup.com]
- Chen J, et al. CAZ‑AVI vs polymyxins (CRE). Infection. 2024;52:19–28. DOI:10.1007/s15010-023-02108-6. [link.springer.com]
- Ong’uti S, et al. Cefiderocol review. Clin Infect Dis. 2022;74(7):1303–1312. DOI:10.1093/cid/ciab757. [academic.oup.com]
- Bassetti M, et al. CREDIBLE‑CR. Lancet Infect Dis. 2021;21(2):226‑240. DOI:10.1016/S1473-3099(20)30796-9. [thelancet.com]
- Dulhunty JM, et al. BLING III. JAMA. 2024;332(8):629‑637. DOI:10.1001/jama.2024.9779. [jamanetwork.com]
- Gatti M, et al. PK/PD target continuous infusion. Antibiotics. 2021;10(11):1311. PMID:34827249. [europepmc.org]
- ECDC. Antimicrobial resistance in the EU/EEA – AER 2023 (pubblicato 2024). Stockholm: ECDC. [ecdc.europa.eu]
- EMA. Medicine shortages – Annual report 2024 (MSSG/SPOC; piattaforma europea). [ema.europa.eu]
- EMA. Public information on medicine shortages (catalogo e comunicazioni). [ema.europa.eu]
- Euronews (conferma EMA). Assenza di segnali di shortage antibiotici inverno 2025/26. [euronews.com]
- Euronews/ECA. Dipendenza da API extra‑UE e criticità strutturali. [euronews.com]
